Pyrazinamide
- Atc Codes:J04AK01
- CAS Codes:98-96-4
- PHARMGKB ID:98-96-4
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Pyrafat, Pyrazinamid; Belgium: Tebrazid; Bulgaria: Pyrazinamid; Cyprus: Piraldina; Czech Republic: Pyrazinamid; Denmark: Pyrazinamid; Estonia: Pyrazinamid; Finland: Tisamid; France: Pirilene; Germany: Pyrafat, Pyrazinamid; Greece: Pyrazinamide; Hungary: Pyrazinamid; Italy: Piraldina; Lithuania: Pyrazinamid; Luxembourg: Tebrazid; Netherlands: Pyrazinamide; Poland: Pyrazinamid; Portugal: Pramide; Romania: Pirazinamida; Slovenia: Pirazinamid; Spain: Pirazinamida.
North America
Canada: Pyrazinamide, Tebrazid; USA: Pyrazinamide.
Latin America
Argentina: Pirazinamida; Brazil: Pirazinon; Mexico: Nizamyl.
Asia
Japan: Pyramide.
Drug combinations
Pyrazinamide, Isoniazid, and Rifampin
Pyrazinamide Ethambutol, Isoniazid, and Rifampin
Chemistry
Pyrazinamide: C~5~H~5~N~3~O. Mw: 123.11. Pyrazinecarboxamide. CAS-98-96-4.
Pharmacologic Category
Antimycobacterials; Antituberculosis Agents. (ATC-Code: J04AK01).
Mechanism of action
Converted to pyrazinoic acid in susceptible strains of Mycobacterium, which lowers pH of environment. Exact mechanism of action unknown.
Therapeutic use
Adjunctive treatment of tuberculosis in combination with other antituberculosis agents.
Pregnancy and lactiation implications
Caution during pregnancy or lactation.
Unlabeled use
Contraindications
Hypersensitivity to pyrazinamide or any component of the formulation. Acute gout. Severe hepatic damage.
Warnings and precautions
Dose-related hepatotoxicity (from transient ALT/AST elevations to jaundice, hepatitis and/or liver atrophy (rare)) occurred. Use with caution in history of alcoholism, and in diabetes mellitus. May inhibit uric acid excretion. Acute gouty attacks reported. Use with caution in chronic gout (contraindicated with acute gout), in porphyria, in renal failure, and in patients receiving concurrent medications associated with hepatotoxicity (particularly with rifampin).